XASXIXC
Market cap3mUSD
Dec 23, Last price
0.07AUD
1D
0.00%
1Q
-10.81%
IPO
-93.23%
Name
Invex Therapeutics Ltd
Chart & Performance
P/E
—
P/S
4.09
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
26.13%
Rev. gr., 5y
%
Revenues
1m
+164.06%
Net income
-2m
L-78.81%
CFO
-2m
L-64.42%
Dividend
Dec 08, 20230.1863 AUD/sh
Earnings
Feb 14, 2025
Profile
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | |
| Income | ||||||
Revenues | 1,212 164.06% | 459 151.90% | 182 | |||
Cost of revenue | 3,346 | 8,687 | 3,863 | |||
Unusual Expense (Income) | ||||||
NOPBT | (2,134) | (8,228) | (3,681) | |||
NOPBT Margin | ||||||
Operating Taxes | (1,212) | (9,344) | (4,113) | |||
Tax Rate | ||||||
NOPAT | (921) | 1,116 | 432 | |||
Net income | (1,642) -78.81% | (7,750) 96.04% | (3,953) 73.09% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (14,001) | |||||
BB yield | 309.85% | |||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (6,025) | (22,470) | (29,339) | |||
| Cash flow | ||||||
Cash from operating activities | (2,444) | (6,869) | (3,377) | |||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | (14,001) | |||||
FCF | (921) | 1,116 | 432 | |||
| Balance | ||||||
Cash | 6,025 | 22,470 | 29,339 | |||
Long term investments | ||||||
Excess cash | 5,964 | 22,447 | 29,330 | |||
Stockholders' equity | 5,688 | 21,231 | 28,481 | |||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 75,312 | 75,154 | 75,154 | |||
Price | 0.06 -70.00% | 0.20 -59.60% | 0.50 -21.43% | |||
Market cap | 4,519 -69.94% | 15,031 -59.60% | 37,201 -21.43% | |||
EV | (1,506) | (7,439) | 7,862 | |||
EBITDA | (2,134) | (8,228) | (3,681) | |||
EV/EBITDA | 0.71 | 0.90 | ||||
Interest | 80 | |||||
Interest/NOPBT | ||||||